Frankfurt
06.12.24
08:01 Uhr
0,000 Euro
0,000
0,00 %
0,00 %
1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.12.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.12.2024 | 1.086 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.12.2024ISIN NameCA33812R1091 FISSION... ► Artikel lesen | |
| 16.12.24 | Nasdaq Stockholm AB: Delisting of Cyxone AB from Nasdaq First North Growth Market | 154 | GlobeNewswire | On December 9, 2024, Cyxone AB was declared bankrupt by Malmö District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial... ► Artikel lesen | |
| 06.12.24 | XFRA 4CX: AUSSETZUNG/SUSPENSION | 178 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCYXONE AB SK-,75... ► Artikel lesen | |
| 12.11.24 | Nasdaq Stockholm AB: Cyxone AB receives observation status | 222 | GlobeNewswire | On November 8, 2024, Cyxone AB (the "Company") disclosed a press release with
information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that an issuer can... ► Artikel lesen | |
| CYXONE Aktie jetzt für 0€ handeln | |||||
| 08.11.24 | Nasdaq Stockholm AB: Lift of Suspension in Cyxone AB at FNSE | 243 | GlobeNewswire | Lifting of Suspension
At Trading Venue FNSE
Issuer: Cyxone AB, LEI: 54930034OH16ROAY4K87
--------------------------------------------------------------------------------
Instruments:... ► Artikel lesen | |
| 26.07.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.07.2024 | 320 | Xetra Newsboard | Das Instrument 1NN ES0105251005 NEINOR HOMES SA EO 8,21 EQUITY wird cum Kapitalmassnahme gehandelt am 26.07.2024 und ex Kapitalmassnahme am 29.07.2024 The instrument 1NN ES0105251005 NEINOR HOMES SA... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 111,20 | -1,85 % | Vervielfachungspotenzial mit KI-Newcomer NetraMark! Palantir und BioNTech in einer Aktie! | "Gamechanger"! "Quantensprung"! "Revolution"! Für die Möglichkeiten von Künstlicher Intelligenz (KI) in der Medizin verwenden Experten zahlreiche Superlative. Fest steht, dass KI riesiges Potenzial... ► Artikel lesen | |
| VALNEVA | 3,716 | -3,98 % | Valneva: Frische Zahlen, neue Prognose - Aktie steigt | Der europäische Impfstoff-Hersteller Valneva hat am Dienstag die Zahlen für das vergangene Geschäftsjahr vorgelegt. Das Unternehmen fasst auch für 2025 weiteres Wachstum mit seinem Reiseimpfstoff-Portfolio... ► Artikel lesen | |
| NOVAVAX | 7,219 | +2,02 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| BAVARIAN NORDIC | 23,410 | +0,82 % | Bavarian Nordic A/S: Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine | Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-income countries.
COPENHAGEN, Denmark... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,560 | -3,03 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,620 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors | Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL®... ► Artikel lesen | |
| ORAGENICS | 0,269 | 0,00 % | Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health | ||
| LEXICON PHARMACEUTICALS | 0,715 | +6,40 % | Lexicon Pharmaceuticals, Inc.: Lexicon Appoints Scott Coiante as Chief Financial Officer | THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,410 | +11,41 % | CStone Pharmaceuticals: CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly) in JAMA | Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The... ► Artikel lesen | |
| NANOSPHERE HEALTH SCIENCES | 0,040 | 0,00 % | Nanosphere Health Sciences Inc (2): Nanosphere Health Sciences to hold AGM Dec. 13 | ||
| OUTLOOK THERAPEUTICS | 1,420 | -2,07 % | Research Analysts Set Expectations for OTLK Q2 Earnings | ||
| GENSCRIPT BIOTECH | 1,700 | +2,41 % | GENSCRIPT BIO (01548): RISK MANAGEMENT AND ESG COMMITTEE - TERMS OF REFERENCE | ||
| KRYSTAL BIOTECH | 177,50 | -0,67 % | Krystal Biotech, Inc.: Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results | Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,448 | -2,18 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study | 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to... ► Artikel lesen | |
| Q32 BIO | 2,360 | -2,48 % | Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata | -- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating... ► Artikel lesen |
Das Unternehmen CYXONE AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.
